Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT-Reference-Cited by-同舟云学术

Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT

Published:2017-04-19 Issue:11 Volume:1 Page:652-661
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Fitzhugh Courtney D.¹²^ORCID,Hsieh Matthew M.²^ORCID,Taylor Tiffani²,Coles Wynona²,Roskom Katherine¹,Wilson Delon¹,Wright Elizabeth³,Jeffries Neal⁴,Gamper Christopher J.⁵^ORCID,Powell Jonathan⁵,Luznik Leo⁵,Tisdale John F.²

Affiliation:

1. Sickle Cell Branch, National Heart, Lung, and Blood Institute (NHLBI),

2. Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and NHLBI,

3. Office of the Clinical Director, NIDDK, and

4. Division of Cardiovascular Sciences, Office of Biostatistics Research, NHLBI, National Institutes of Health, Bethesda, MD; and

5. Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

Abstract

Key Points Patients with SCD and severe organ damage can tolerate nonmyeloablative conditioning with no transplant-related mortality. Posttransplant cyclophosphamide prevents severe GVHD, increases engraftment, and improves the success rate for haploidentical HSCT.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/11/652/877041/advances002972.pdf

Reference60 articles.

1. Mortality in sickle cell disease. Life expectancy and risk factors for early death;Platt;N Engl J Med,1994

2. Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia;Fitzhugh;PLoS One,2015

3. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients;Powars;Medicine (Baltimore),2005

4. Population estimates of sickle cell disease in the U.S;Hassell;Am J Prev Med,2010

5. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now;Hsieh;Blood,2011

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurovascular Manifestations of Sickle Cell Disease;Hemato;2024-08-09

2. Gene therapies on the horizon for sickle cell disease: a clinician’s perspective;Expert Review of Hematology;2024-07-31

3. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease;Blood;2024-06-20

4. Low dose post-transplant cyclophosphamide and sirolimus induce mixed chimerism with CTLA4-Ig or lymphocyte depletion in an MHC-mismatched murine allotransplantation model;Bone Marrow Transplantation;2024-02-12

5. Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review;Cell Transplantation;2024-01